Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Prospective Study of Chemotherapy in Combination with Cytokine-induced Killer Cells in Patients Suffering from Advanced Non-small Cell Lung Cancer

In English

Författare

  • Changping Wu
  • Jingting Jiang
  • Liangrong Shi
  • Ning Xu

Summary, in English

The present study evaluated the clinical efficacy of chemotherapy in combination with cytokine-induced killer (CIK) biotherapy compared to the chemotherapy alone. Fifty-nine advanced non-small cell lung cancer (NSCLC) patients were randomly divided into two groups, group A (chemotherapy, alone, including docetaxel 75 mg/m(2), day 1; cisplatin, 25 mg/m(2), days 1-4, tri-weekly) and group B (chemotherapy plus CIK cell transfusion). Autologous ClK cells were induced from the patients' peripheral mononuclear cells in vitro and separated by cytometry and then transfused back the patients. The host cellular immune function, clinical curative effects and quality of life (QOL) were examined and were compared between the two groups. The host immune function was enhanced and QOL was improved in the patients treated by chemotherapy, plus CIK biotherapy compared to the patients treated by chemotherapy alone. The overall response rate (ORR) was 43.3 % and 44.8% in groups A and B, respectively. The disease control rate (DCR) was higher in group B than in group A (89.7% vs. 65.5%, p=0.030). The time to progression was 4.67 months (95% CI 3.98-6.02 months) in group A and 6.65 months (95% CI 4.70-7.30 months) in group B and the median survival time was 11.0 months (95% CI 7.88-14.1 months) in group A and 15.0 months (95% CI 11.04-18.96 months) in group B. Compared to patients in group A, the patients in group B had significantly longer progression-free survival (p=0.042) and overall survival (p=0.029). No severe side-effects occurred in the ClK cell transfusion patients. It was concluded that chemotherapy plus CIK cells has potential benefits compared to chemotherapy alone in patients suffering from advanced NSCLC and autologous CIK cell transfusion has no obvious side-effects.

Publiceringsår

2008

Språk

Engelska

Sidor

3997-4002

Publikation/Tidskrift/Serie

Anticancer research

Volym

28

Issue

6B

Dokumenttyp

Artikel i tidskrift

Förlag

International Institute of Cancer Research

Ämne

  • Cancer and Oncology

Nyckelord

  • immunotherapy
  • Non-small cell lung cancer
  • cytokine-induced killer cells

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1791-7530